Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oxaliplatin + irinotecan + capecitabine + fluorouracil + bevacizumab
- Development stage
- Preclinical
- Lead developer
- Sanofi
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination chemotherapy regimen consisting of oxaliplatin (a platinum compound), irinotecan (a topoisomerase I inhibitor), capecitabine (an oral fluoropyrimidine), fluorouracil (5-FU, a fluoropyrimidine), and bevacizumab (a VEGF inhibitor). This combination represents an expanded version of established regimens like FOLFOXIRI (fluorouracil, oxaliplatin, irinotecan) with the addition of capecitabine and bevacizumab. The chemotherapy components work through different mechanisms to destroy rapidly dividing cancer cells, while bevacizumab inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
02
Targets
Beyond the preview
Go deeper on oxaliplatin + irinotecan + capecitabine + fluorouracil + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oxaliplatin + irinotecan + capecitabine + fluorouracil + bevacizumab.